Ocuphire Pharma to Present at Euretina and Retina Society Conferences in OctoberGlobeNewsWire • 10/06/23
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.GlobeNewsWire • 09/27/23
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.PRNewsWire • 09/27/23
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in SeptemberGlobeNewsWire • 09/07/23
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer SymposiumGlobeNewsWire • 08/28/23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 08/11/23
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in AugustGlobeNewsWire • 08/08/23
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation SummitGlobeNewsWire • 07/26/23
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/10/23
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual ConferenceGlobeNewsWire • 06/27/23
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual ConferenceGlobeNewsWire • 06/21/23
Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023GlobeNewsWire • 06/12/23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 05/15/23
Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's WhyZacks Investment Research • 05/08/23
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and EyeceleratorGlobeNewsWire • 05/02/23
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical ProgramsGlobeNewsWire • 04/25/23
Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case - Ocuphire Pharma (NASDAQ:OCUP)Benzinga • 04/21/23
Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to TradeZacks Investment Research • 04/21/23
Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 04/21/23